Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antimicrobial Effectiveness

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in Pakistan: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.

The Journal of antimicrobial chemotherapy·2025

Same author

Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in Ukraine: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.

The Journal of antimicrobial chemotherapy·2025

Same author

Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in Türkiye: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.

The Journal of antimicrobial chemotherapy·2025

Same author

Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in Kuwait and the United Arab Emirates: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.

The Journal of antimicrobial chemotherapy·2025

Same author

Antimicrobial resistance among agents of hospital-acquired lower respiratory tract infection in the UK and Ireland: trends from 2008/2009 to 2018/2019.

The Journal of antimicrobial chemotherapy·2025

Same author

Modification of antimicrobial susceptibility testing methods.

The Journal of antimicrobial chemotherapy·2025

Search research articles

Related Experiment Video

Updated: Jun 3, 2026

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

Published on: April 18, 2019

Comparative activity of carbapenem testing: the COMPACT study.

Patrice Nordmann¹, Juan J Picazo, Reinier Mutters

¹Department Bactériologie-Virologie, Unite INSERM 914, Hôpital de Bicêtre, Le-Kremlin-Bicêtre, France.

The Journal of Antimicrobial Chemotherapy

|March 12, 2011

Summary

Doripenem demonstrates strong activity against Gram-negative bacteria, outperforming imipenem and matching meropenem. It shows particular efficacy against Pseudomonas species, even in some cases of resistance to other carbapenems.

More Related Videos

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria

Published on: December 14, 2016

Related Experiment Videos

Last Updated: Jun 3, 2026

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

Published on: April 18, 2019

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria

Published on: December 14, 2016

Area of Science:

Microbiology
Infectious Diseases
Pharmacology

Background:

Doripenem is a novel carbapenem antibiotic recently introduced in Europe.
Serious Gram-negative bacterial infections pose a significant challenge in hospitalized patients.

Purpose of the Study:

To compare the in vitro activity of doripenem against imipenem and meropenem.
To evaluate the susceptibility of common Gram-negative pathogens to these carbapenems.

Main Methods:

The COMParative Activity of Carbapenem Testing (COMPACT) study involved 4498 Gram-negative isolates from 80 centers across Europe, the Middle East, and Africa.
Minimum Inhibitory Concentrations (MICs) were determined using Etest and broth microdilution methods.
Susceptibility was interpreted using CLSI, EUCAST, and FDA breakpoints.

Main Results:

Doripenem exhibited lower MIC(90) values than imipenem and meropenem for overall Gram-negative isolates (8 mg/L vs. ≥64 mg/L and 32 mg/L, respectively).
Doripenem was most potent against Pseudomonas species (MIC(90) of 16 mg/L) compared to imipenem and meropenem (≥64 mg/L).
Enterobacteriaceae were highly susceptible to all tested carbapenems, while Acinetobacter baumannii showed resistance.

Conclusions:

Doripenem displays excellent in vitro activity against Gram-negative bacteria, generally exceeding imipenem and matching meropenem.
Doripenem demonstrated superior activity against Pseudomonas species compared to both imipenem and meropenem.
A notable finding was doripenem's activity against some isolates resistant to imipenem and/or meropenem.